Biotech Values

[DewDiligence]

>> 10mg may be used sub-Q or topical… patients may be able to treat themselves, or more frequent appts with less drug being used. <<

I rather doubt the FDA would approve self-administration of an AMD drug that is not a pill, and hence I found Levitt’s comment about a subcutaneous formulation odd to say the least.

As for the dosing schedule of the existing IV formulation, anything more frequent than monthly is too frequent, IMHO. During the initial four-week loading-dose period, it’s reasonable to expect patients to come into the clinic weekly. But it’s not reasonable to expect patients to continue to come in weekly, or even bi-weekly, for treatment after treatment.